Nothing Special   »   [go: up one dir, main page]

DK2637690T3 - Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration - Google Patents

Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration

Info

Publication number
DK2637690T3
DK2637690T3 DK11839071.5T DK11839071T DK2637690T3 DK 2637690 T3 DK2637690 T3 DK 2637690T3 DK 11839071 T DK11839071 T DK 11839071T DK 2637690 T3 DK2637690 T3 DK 2637690T3
Authority
DK
Denmark
Prior art keywords
high concentration
tnf alpha
liquid high
antibody formulations
alpha antibody
Prior art date
Application number
DK11839071.5T
Other languages
English (en)
Inventor
Carsten Weber
Laura Redden
Michael Neu
Martin Gastens
Alexander Feick
Susan K Paulson
Tong Zhu
Markus Tschoepe
Wolfgang Fraunhofer
Original Assignee
Abbvie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46051586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2637690(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotechnology Ltd filed Critical Abbvie Biotechnology Ltd
Application granted granted Critical
Publication of DK2637690T3 publication Critical patent/DK2637690T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK11839071.5T 2010-11-11 2011-11-11 Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration DK2637690T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41272810P 2010-11-11 2010-11-11
US41396010P 2010-11-15 2010-11-15
PCT/US2011/060388 WO2012065072A2 (en) 2010-11-11 2011-11-11 IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS

Publications (1)

Publication Number Publication Date
DK2637690T3 true DK2637690T3 (da) 2017-01-02

Family

ID=46051586

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11839071.5T DK2637690T3 (da) 2010-11-11 2011-11-11 Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration

Country Status (29)

Country Link
US (5) US8821865B2 (da)
EP (1) EP2637690B1 (da)
JP (3) JP5919606B2 (da)
KR (1) KR101841527B1 (da)
CN (2) CN103458926B (da)
AU (2) AU2011325974B2 (da)
BR (1) BR112013011699B1 (da)
CA (1) CA2815689C (da)
CY (1) CY1118373T1 (da)
DK (1) DK2637690T3 (da)
ES (1) ES2601202T3 (da)
HK (1) HK1189162A1 (da)
HR (1) HRP20161753T1 (da)
HU (1) HUE029457T2 (da)
IL (1) IL226217A (da)
LT (1) LT2637690T (da)
ME (1) ME02506B (da)
MX (1) MX344727B (da)
NZ (1) NZ609469A (da)
PL (1) PL2637690T3 (da)
PT (1) PT2637690T (da)
RS (1) RS55385B1 (da)
RU (2) RU2015154965A (da)
SG (2) SG2014015069A (da)
SI (1) SI2637690T1 (da)
SM (1) SMT201600443B (da)
TW (2) TWI603739B (da)
WO (1) WO2012065072A2 (da)
ZA (1) ZA201406542B (da)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
NZ627177A (en) 2005-05-16 2016-02-26 Abbvie Biotechnology Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
JP5505760B2 (ja) 2005-09-27 2014-05-28 ティッシュテク・インコーポレーテッド 羊膜調製物及び精製組成物及びその使用方法
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
ES2532461T3 (es) 2007-12-26 2015-03-27 Xencor, Inc. Variantes de FC con enlazamiento alterado a FCRN
ES2939310T3 (es) 2008-10-27 2023-04-20 Genalyte Inc Biosensores basados en sondeo y detección ópticos
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2717888B1 (en) 2011-06-10 2020-09-09 Tissuetech, Inc. Methods of processing fetal support tissues
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013186230A1 (en) * 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
WO2014011813A1 (en) 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PE20191815A1 (es) 2012-09-07 2019-12-27 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
PT2919801T (pt) * 2012-10-26 2020-07-30 Lupin Atlantis Holdings Sa Composição farmacêutica estável da proteína de fusão tnfr:fc etanercept
WO2014099636A1 (en) * 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
CA2898262A1 (en) 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
AU2014240431A1 (en) 2013-03-14 2015-08-27 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
KR20150129033A (ko) 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
SI3021833T2 (sl) 2013-07-19 2022-08-31 Hexal Aktiengesellschaft Postopki in formulacije, ki dopuščajo modulacijo imunskih odzivov, povezanih z dajanjem biofarmacevtskega zdravila
SG10201913952TA (en) * 2013-09-11 2020-03-30 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
IN2014MU01248A (da) * 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
DK2946765T3 (da) 2014-05-23 2016-10-31 Ares Trading Sa Flydende farmaceutisk sammensætning
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
WO2016000813A1 (en) * 2014-06-30 2016-01-07 Merck Patent Gmbh Anti-tnfa antibodies with ph-dependent antigen binding
KR102500075B1 (ko) * 2014-10-08 2023-02-16 아지노모토 가부시키가이샤 평가 방법, 평가 장치, 평가 프로그램, 평가 시스템, 및 단말 장치
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TW201642914A (zh) 2015-02-23 2016-12-16 組織科技股份有限公司 用於治療眼部疾病及失調的裝置及方法
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
CA2984443A1 (en) 2015-05-20 2016-11-24 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
TWI833685B (zh) * 2015-07-31 2024-03-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 預測抗體之生物利用度之方法
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2017136433A1 (en) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
SG11201900201YA (en) 2016-08-16 2019-02-27 Regeneron Pharma Methods for quantitating individual antibodies from a mixture
AU2017345454B2 (en) 2016-10-19 2024-10-31 Invenra Inc. Antibody constructs
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
IL295211B2 (en) 2016-10-25 2024-09-01 Regeneron Pharma Methods and systems for analysis of chromatography data
CA3045857A1 (en) 2016-12-22 2018-06-28 Universita Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
RU2665966C2 (ru) * 2016-12-30 2018-09-05 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
RU2756619C2 (ru) * 2017-03-16 2021-10-04 ЭлДжи КЕМ, ЛТД. Жидкая композиция антитела против TNF альфа
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
CN111201042B (zh) 2017-09-19 2024-05-10 里珍纳龙药品有限公司 减少粒子形成的方法以及由其形成的组合物
CN111491664A (zh) * 2017-09-20 2020-08-04 阿尔沃科技Hf公司 阿达木单抗的药物制剂
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2019212993A1 (en) * 2018-04-30 2019-11-07 Genalyte, Inc. Methods and compositions for point of care measurement of the bioavailability of therapeutic biologics
AU2019283314B2 (en) 2018-06-05 2024-11-07 GammaDelta Therapeutics Limited BTNL3/8 targeting constructs for delivery of payloads to the gastrointestinal system
US20220257600A1 (en) 2018-06-20 2022-08-18 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20210363233A1 (en) 2018-06-20 2021-11-25 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
AU2019299321A1 (en) 2018-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Use of multiple hydrophobic interaction chromatography for preparing a polypeptide from a mixture
KR20210114989A (ko) 2019-02-18 2021-09-24 일라이 릴리 앤드 캄파니 치료 항체 제제
CA3133577A1 (en) * 2019-03-18 2020-09-24 Alvotech Hf Aqueous formulations of tnf-alpha antibodies in high concentrations
EP3998063A4 (en) * 2019-07-08 2023-03-15 MORESCO Corporation COMPOSITIONS FOR PREPARING MICROEMULSION, MICROEMULSION, METHOD FOR PRODUCING COMPOSITION AND MICROEMULSION, AND USE OF MICROEMULSION
JP6667043B1 (ja) * 2019-10-25 2020-03-18 株式会社Moresco マイクロエマルション、及びマイクロエマルションの利用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
DE69027121T3 (de) 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
PT929578E (pt) 1996-02-09 2003-09-30 Abbott Lab Bermuda Ltd Anticorpos humanos que se ligam a tnfalfa humano
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2251342A1 (en) 1997-10-23 1999-04-23 Yutaka Hirao Room temperature storable immunoglobulin preparation for intravenous injection
EP1174148A4 (en) 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME
JP4516711B2 (ja) 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
JP4555436B2 (ja) * 2000-06-29 2010-09-29 富士通株式会社 薄膜樹脂基板への樹脂モールド方法及び高周波モジュール
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
SE0003045D0 (sv) 2000-08-29 2000-08-29 Probi Ab New method
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002096461A1 (en) 2001-05-25 2002-12-05 Abbott Gmbh & Co. Kg Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
EP1391209A4 (en) 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
PT1397155E (pt) 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
EP1409018B1 (en) * 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
JP4342941B2 (ja) 2001-08-29 2009-10-14 中外製薬株式会社 抗体含有安定化製剤
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
DK1441589T3 (da) 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
GB0202633D0 (en) 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
WO2003068260A1 (en) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CA2490423A1 (en) 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
KR20130001318A (ko) 2002-07-19 2013-01-03 애보트 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
DK3417875T3 (da) 2003-02-10 2020-08-31 Biogen Ma Inc Immunglobulinformulering og fremgangsmåde til fremstilling deraf
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
MXPA05009135A (es) 2003-02-28 2005-10-20 Ares Trading Sa Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
DK2335725T3 (da) 2003-04-04 2017-01-23 Genentech Inc Højkoncentrerede antistof- og proteinformuleringer
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
JP4219932B2 (ja) 2003-10-01 2009-02-04 協和発酵キリン株式会社 抗体の安定化方法及び安定化された溶液状抗体製剤
WO2005063291A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
EP1987843A3 (en) 2004-03-12 2011-10-26 Intercell AG Method for solubilising peptide mixtures
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
AU2005249232B2 (en) 2004-06-01 2010-08-05 Ares Trading S.A. Method of stabilizing proteins
EP1807111A4 (en) 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1841456A2 (en) 2005-01-28 2007-10-10 Wyeth Stabilized liquid polypeptide formulations
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
NZ627177A (en) 2005-05-16 2016-02-26 Abbvie Biotechnology Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
WO2006125207A2 (en) 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
ATE501248T1 (de) 2005-07-02 2011-03-15 Arecor Ltd Stabile wässrige systeme mit proteinen
WO2007016562A2 (en) 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
EA014513B1 (ru) 2005-08-03 2010-12-30 Иммьюноджен, Инк. Композиция иммуноконъюгата
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
NZ608431A (en) 2005-11-01 2014-11-28 Abbvie Biotechnology Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
PT1986612E (pt) 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
SG10201406358SA (en) 2006-04-05 2014-12-30 Abbvie Biotechnology Ltd Antibody purification
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US7571225B2 (en) 2006-06-29 2009-08-04 Stratavia Corporation Standard operating procedure automation in database administration
CN101484199B (zh) 2006-06-30 2014-06-25 艾伯维生物技术有限公司 自动注射装置
CA2842959A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
KR20090060453A (ko) 2006-09-25 2009-06-12 메디뮨 엘엘씨 안정화된 항체 제제 및 그것의 용도
CL2007002880A1 (es) 2006-10-06 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
RU2486296C2 (ru) 2006-10-27 2013-06-27 Эбботт Байотекнолоджи Лтд. КРИСТАЛЛИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFα
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
KR20090110349A (ko) 2007-02-16 2009-10-21 와이어쓰 소르비톨을 함유하는 단백질 제제
MX2009011367A (es) 2007-04-26 2010-03-22 Bayer Healthcare Llc Estabilizacion de soluciones liquidas de proteina recombinante para el almacenamiento congelado.
EP2144629A1 (en) 2007-05-02 2010-01-20 F. Hoffmann-Roche AG Method for stabilizing a protein
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
EP2150537A4 (en) 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
WO2008150490A2 (en) 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
JP5759722B2 (ja) 2007-08-28 2015-08-05 アッヴィ バイオテクノロジー リミテッド アダリムマブの結合蛋白質を含む組成物及び方法
CN104645329A (zh) * 2007-11-30 2015-05-27 Abbvie公司 蛋白制剂及其制备方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20090271164A1 (en) 2008-01-03 2009-10-29 Peng Joanna Z Predicting long-term efficacy of a compound in the treatment of psoriasis
US8187836B2 (en) 2008-01-15 2012-05-29 Abbott Laboratories Mammalian expression vectors and uses thereof
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
MX2010010503A (es) 2008-03-24 2010-11-09 Abbott Biotech Ltd Metodos y composiciones para tratar perdida osea.
JP5677411B2 (ja) 2009-04-29 2015-02-25 アッヴィ バイオテクノロジー リミテッド 自動注入機器
NZ613809A (en) * 2009-05-04 2015-02-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CN102959088A (zh) 2010-02-02 2013-03-06 艾博特生物技术有限公司 用于预测对TNF-α抑制剂治疗的反应性的方法和组合物
PL2575884T3 (pl) 2010-06-03 2018-12-31 Abbvie Biotechnology Ltd Zastosowania i kompozycje do leczenia ropni mnogich pach (HS)
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤

Also Published As

Publication number Publication date
US20190211093A1 (en) 2019-07-11
CY1118373T1 (el) 2017-06-28
WO2012065072A3 (en) 2012-07-26
JP2013543868A (ja) 2013-12-09
TW201641119A (zh) 2016-12-01
AU2011325974B2 (en) 2016-10-27
AU2016202136A1 (en) 2016-04-28
TW201244736A (en) 2012-11-16
JP6062582B2 (ja) 2017-01-18
AU2011325974A1 (en) 2013-05-09
HUE029457T2 (en) 2017-02-28
IL226217A0 (en) 2013-07-31
JP2016128466A (ja) 2016-07-14
CN103458926B (zh) 2016-10-26
TWI603739B (zh) 2017-11-01
WO2012065072A2 (en) 2012-05-18
BR112013011699A2 (pt) 2015-09-29
EP2637690B1 (en) 2016-09-21
EP2637690A2 (en) 2013-09-18
ES2601202T3 (es) 2017-02-14
SG190069A1 (en) 2013-06-28
EP2637690A4 (en) 2014-04-30
MX344727B (es) 2017-01-05
US8821865B2 (en) 2014-09-02
BR112013011699B1 (pt) 2019-04-24
SG2014015069A (en) 2014-07-30
MX2013005341A (es) 2013-07-05
TWI606840B (zh) 2017-12-01
US20220010005A1 (en) 2022-01-13
RU2013126655A (ru) 2014-12-20
SI2637690T1 (sl) 2016-11-30
RU2015154965A (ru) 2019-01-16
KR20130135266A (ko) 2013-12-10
PT2637690T (pt) 2016-12-27
PL2637690T3 (pl) 2017-03-31
US20120263731A1 (en) 2012-10-18
SMT201600443B (it) 2017-01-10
US20160017030A1 (en) 2016-01-21
CA2815689C (en) 2016-11-22
IL226217A (en) 2017-08-31
JP5919606B2 (ja) 2016-05-18
US20140377275A1 (en) 2014-12-25
LT2637690T (lt) 2016-10-25
CN103458926A (zh) 2013-12-18
ZA201406542B (en) 2015-09-30
KR101841527B1 (ko) 2018-03-23
ME02506B (me) 2017-02-20
CN105854016A (zh) 2016-08-17
NZ609469A (en) 2015-02-27
RU2639386C2 (ru) 2017-12-21
HRP20161753T1 (hr) 2017-02-10
HK1189162A1 (zh) 2014-05-30
JP2016172740A (ja) 2016-09-29
CA2815689A1 (en) 2012-05-18
RS55385B1 (sr) 2017-03-31

Similar Documents

Publication Publication Date Title
DK2637690T3 (da) Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration
CY2019040I2 (el) Aνti-il-23 αντισωματα
HRP20170983T1 (hr) Pripravci s visokom koncentracijom antitijela
BR112014028600A2 (pt) formulações de anticorpo monoclonal de alta concentração
EP2934587A4 (en) LIQUID FORMULATIONS FOR ANTI-TNFALPHA ANTIBODY
ES2985395T3 (es) Formulaciones líquidas que contienen anticuerpos estabilizados
CO7020859A2 (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
DK2643018T3 (da) Anti-il-6-antistoffer til behandling af oral mucositis
BR112012030311A2 (pt) anticorpo
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
BR112012024820A2 (pt) composição de limpeza líquida
CO6801637A2 (es) Formulaciones de anticuerpos
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
BR112012030765A8 (pt) composição líquida estéril
CO6791565A2 (es) Anticuerpos anti-notch1